A Pilot Study of 18F-FLT PET/CT in Pediatric Lymphoma

Costantini, Danny L.; Vali, Reza; McQuattie, Susan; Chan, Jonathan; Punnett, Angela; Weitzman, Shiela; Shammas, Amer; Charron, Martin

doi:10.1155/2016/6045894

Cited by 9 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When using 11 C-MET, SUV max did not significantly differ between both groups, although it tended to be lower in patients with GBM have not yet been reported to be appropriate tools for investigating PCNSL. 2,23 The 68 Ga-pentixafor, which is a tracer binding to the CXCR4 chemokine receptor, was similarly used for investigating GBM 24 and PCNSL, 25 whereas no study to date compared its uptake in both tumor types. We can therefore conclude that, by combining advanced MRI sequences with using a PET radiopharmaceutical, either 18 F-FDG or 11 C-MET, PCNSL differentiation from other brain malignancies could be rendered possible, with high probability.…”

Section: Discussionmentioning

confidence: 99%

“…Other radiopharmaceuticals in use for the investigation of brain tumors ( 18 F-thymidine [ 18 F-FLT], 18 F-fluorodopa [ 18 F-DOPA], 18 F-fluoroethyl-L tyrosine [ 18 F-FET]) have not yet been reported to be appropriate tools for investigating PCNSL 2,23 . The 68 Ga-pentixafor, which is a tracer binding to the CXCR4 chemokine receptor, was similarly used for investigating GBM 24 and PCNSL, 25 whereas no study to date compared its uptake in both tumor types.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

First-in-Man Noninvasive Initial Diagnostic Approach of Primary CNS Lymphoma Versus Glioblastoma Using PET With 18F-Fludarabine and l-[methyl-11C]Methionine

et al. 2022

View full text Add to dashboard Cite

Objectives: This study sought to assess 18 F-fludarabine ( 18 F-FLUDA) PET/ CT's ability in differentiating primary central nervous system lymphomas (PCNSLs) from glioblastoma multiformes (GBMs). Patients and Methods: Patients harboring either PCNSL (n = 8) before any treatment, PCNSL treated using corticosteroids (PCNSLh; n = 10), or GBM (n = 13) were investigated with conventional MRI and PET/CT, using 11 C-MET and 18 F-FLUDA. The main parameters measured with each tracer were SUV T and T/N ratios for the first 30 minutes of 11 C-MET acquisition, as well as at 3 different times after 18 F-FLUDA injection. The early 18 F-FLUDA uptake within the first minute of injection was equally considered, whereas this parameter was combined with the later uptakes to obtain R FLUDA 2 and R FLUDA 3 ratios. Results: No significant differences in 11 C-MET uptakes were observed among PCNSL, PCNSLh, and GBM. With 18 F-FLUDA, a clear difference in dynamic GBM uptake was observed, which decreased over time after an early maximum, as compared with that of PCNSL, which steadily increased over time, PCNSLh exhibiting intermediate values. The most discriminative parameters consisting of R FLUDA 2 and R FLUDA 3 integrated the early tracer uptake (first 60 seconds), thereby provided 100% specificity and sensitivity. Conclusions: 18 F-FLUDA was shown to likely be a promising radiopharmaceutical for differentiating PCNSL from other malignancies, although a pretreatment with corticosteroids might compromise this differential diagnostic ability. The diagnostic role of 18 F-FLUDA should be further investigating, along with its potential of defining therapeutic strategies in patients with PCNSL, while assessing the treatments' effectiveness.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

First-in-Man Noninvasive Initial Diagnostic Approach of Primary CNS Lymphoma Versus Glioblastoma Using PET With 18F-Fludarabine and l-[methyl-11C]Methionine

et al. 2022

View full text Add to dashboard Cite

show abstract

“…76,77 Its use as a biomarker in childhood cancer is mostly limited to preclinical models of glioma, 78,79 Ewing sarcoma, 80 and rhabdomosarcoma, 81 and a pilot study of 18 F-FLT uptake in pediatric patients with lymphoma. 82 Conceivably, uptake of this tracer might be a superior response biomarker for agents that primarily act by arresting cell proliferation, such as with CDK4/6 inhibitors. 83 In fact, changes in 18 In our experiments, selumetinib was able to slow tumor growth whereas trametinib did not-even though each drug suppressed phospho-ERK1/2.…”

Section: Discussionmentioning

confidence: 99%

“…Although not all clinical trials have shown a one‐to‐one correlation with cell proliferation, increased 18 F‐FLT uptake seems to correlate at least as well as 18 F‐FDG with unfavorable outcomes 76,77 . Its use as a biomarker in childhood cancer is mostly limited to preclinical models of glioma, 78,79 Ewing sarcoma, 80 and rhabdomosarcoma, 81 and a pilot study of 18 F‐FLT uptake in pediatric patients with lymphoma 82 . Conceivably, uptake of this tracer might be a superior response biomarker for agents that primarily act by arresting cell proliferation, such as with CDK4/6 inhibitors 83 .…”

Section: Discussionmentioning

confidence: 99%

Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts

Butler

Schwettmann

Geboers

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background: Malignant peripheral nerve sheath tumor (MPNST) is an aggressive form of soft-tissue sarcoma (STS) in children. Despite intensive therapy, relatively few children with metastatic and unresectable disease survive beyond three years. RAS pathway activation is common in MPNST, suggesting MEK pathway inhibition as a targeted therapy, but the impact on clinical outcome has been small to date. Procedure: We conducted preclinical pharmacokinetic (PK) and pharmacodynamic studies of two MEK inhibitors, trametinib and selumetinib, in two MPNST models and analyzed tumors for intratumor drug levels. We then investigated 3′-deoxy-3′-[ 18 F]fluorothymidine (18 F-FLT) PET imaging followed by 18 F-FDG PET/CT imaging of MPNST xenografts coupled to short-term or longer-term treatment with selumetinib focusing on PET-based imaging as a biomarker of MEK inhibition. Results: Trametinib decreased pERK expression in MPNST xenografts but did not prolong survival or decrease Ki67 expression. In contrast, selumetinib prolonged survival of animals bearing MPNST xenografts, and this correlated with decreased pERK and Ki67 staining. PK studies revealed a significantly higher fraction of unbound selumetinib within a responsive MPNST xenograft model. Thymidine uptake, assessed by 18 F-FLT PET/CT, positively correlated with Ki67 expression in different xenograft models and in response to selumetinib. Conclusion: The ability of MEK inhibitors to control MPNST growth cannot simply be predicted by serum drug levels or drug-induced changes in pERK expression. Tumor cell proliferation assessed by 18 F-FLT PET imaging might be useful as an early response marker to targeted therapies, including MEK inhibition, where a primary effect is cellcycle arrest.

show abstract

“…blizn wywołanych terapią), co umożliwia dokładniejsze określenie rokowania [19]. W przypadku badań radioizotopowych istnieje jednak ryzyko wyniku fałszywie dodatniego lub fałszywie ujemnego ze względu na fizjologiczne wysokie gromadzenie radioznacznika w grasicy oraz w obszarach intensywnego wzrostu kości [20].…”

Section: • Chłoniak Złośliwyunclassified

Obrazowanie radioizotopowe w onkologii pediatrycznej – przegląd metod

Radzińska¹,

Zając

Pietrzak

et al. 2019

LOS

View full text Add to dashboard Cite

StreszczenieDo najczęstszych chorób onkologicznych występujących u pacjentów pediatrycznych należą: białaczki, chłoniaki, nowotwory złośliwe ośrodkowego układu nerwowego (OUN) oraz neuroblastoma. Częste zachorowania oraz ograniczona czułość i swoistość konwencjonalnych metod obrazowych sugeruje konieczność rozszerzenia postępowania diagnostycznego wobec tej szczególnej grupy chorych o procedury wysokospecjalistyczne, wśród których przydatne wydają się być badania radioizotopowe.AbstractThe most common malignancies observed in paediatric patients are leukemia, lymphoma, central nervous system (CNS) malignant neoplasms and neuroblastoma. Increasing number of new cases of the diseases and limited sensitivity and specificity of the conventional imaging methods in this important and susceptible group of patients suggest the necessity to include the advanced imaging procedures into clinical management, among which radioisotope examinations seem to be valuable.

show abstract

A Pilot Study of 18F-FLT PET/CT in Pediatric Lymphoma

Cited by 9 publications

References 19 publications

First-in-Man Noninvasive Initial Diagnostic Approach of Primary CNS Lymphoma Versus Glioblastoma Using PET With 18F-Fludarabine and l-[methyl-11C]Methionine

First-in-Man Noninvasive Initial Diagnostic Approach of Primary CNS Lymphoma Versus Glioblastoma Using PET With 18F-Fludarabine and l-[methyl-11C]Methionine

Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts

Obrazowanie radioizotopowe w onkologii pediatrycznej – przegląd metod

Contact Info

Product

Resources

About